Talk:Abnormal Development - Thalidomide: Difference between revisions

From Embryology
Line 18: Line 18:
Proc Natl Acad Sci U S A. 2009 May 26;106(21):8573-8. Epub 2009 May 11.
Proc Natl Acad Sci U S A. 2009 May 26;106(21):8573-8. Epub 2009 May 11.
PMID: 19433787
PMID: 19433787
===Thalidomide as a multi-template for development of biologically active compounds.===
Hashimoto Y.
Arch Pharm (Weinheim). 2008 Sep;341(9):536-47. Review.
PMID: 18389516


===Shedding light on an old mystery: thalidomide suppresses survival pathways to induce limb defects.===
===Shedding light on an old mystery: thalidomide suppresses survival pathways to induce limb defects.===

Revision as of 10:06, 9 September 2010

Historic Reference

Arch Environ Health. 1962 Aug;5:100-5. Thalidomide embryopathy. LENZ W, KNAPP K.

PMID: 14464040 [PubMed - indexed for MEDLINE] http://www.ncbi.nlm.nih.gov/pubmed/14464040

References

Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC).

Rafiee P, Stein DJ, Nelson VM, Otterson MF, Shaker R, Binion DG. Am J Physiol Gastrointest Liver Physiol. 2010 Feb;298(2):G167-76. Epub 2009 Nov 19. PMID: 19926820

Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation.

Therapontos C, Erskine L, Gardner ER, Figg WD, Vargesson N. Proc Natl Acad Sci U S A. 2009 May 26;106(21):8573-8. Epub 2009 May 11. PMID: 19433787

Thalidomide as a multi-template for development of biologically active compounds.

Hashimoto Y. Arch Pharm (Weinheim). 2008 Sep;341(9):536-47. Review. PMID: 18389516

Shedding light on an old mystery: thalidomide suppresses survival pathways to induce limb defects.

Cell Cycle. 2008 May 1;7(9):1121-7. Epub 2008 Feb 14.

Knobloch J, Rüther U.

Institute for Animal Developmental and Molecular Biology, Heinrich-Heine-University, Düsseldorf, Germany. juergen.knobloch@uk-koeln.de Abstract Many hypotheses have been proposed to explain the molecular mechanism of thalidomide teratogenicity, in particular regarding to limb defects. Most experimental evidence in vivo has been provided for a model that suggests the generation of oxidative stress by thalidomide with subsequent downregulation of Wnt and Akt survival pathways. As a consequence apoptosis is induced during early embryonic limb development resulting in limb truncations. Here we summarize and discuss the relevant data supporting this hypothesis. We extend this model by presenting new data demonstrating an involvement of the transcription factors Tbx5 and Sall4 in thalidomide-induced molecular pathology. Finally, we discuss a possible participation of other stress-responsive and/or pro-apoptotic transcription factors in the mechanism of thalidomide teratogenicity.

PMID: 18418038

Benegbi M. 45 years later...where do we stand? Can J Clin Pharmacol. 2007 Winter;14(1):e37-9.

Li PK, Pandit B, Sackett DL, Hu Z, Zink J, Zhi J, Freeman D, Robey RW, Werbovetz K, Lewis A, Li C. A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activities. Mol Cancer Ther. 2006 Feb;5(2):450-6.